Starting statins within a year of a diabetes diagnosis cut dementia risk 15%

People who started taking a statin within a year of being diagnosed with type 2 diabetes had a 15% lower relative risk of developing dementia over the following decade than those who did not start the drug, according to a nationwide Danish study presented at the European Society of Cardiology’s 2026 congress. The finding comes from Dr. Tummas Ternhamar of Copenhagen University Hospital, who led the analysis of national health registers covering 132,585 people newly diagnosed with type 2 diabetes. None of them had taken a statin before their diagnosis, which let researchers isolate what happened after diabetes entered the picture rather than measuring decades of prior statin use.

Type 2 diabetes has long been linked to a higher risk of later dementia, through pathways that include damaged blood vessels in the brain and chronic inflammation. Statins are already standard treatment for the high cholesterol that often accompanies diabetes, so the open question was never whether people with diabetes should take them, but whether starting early, rather than waiting, changed anything for the brain specifically. Guidelines from cardiology groups already recommend statins for most adults with type 2 diabetes on cardiovascular grounds alone, meaning the new finding does not change who should be offered the drug so much as it strengthens the case for not delaying that offer.

A Danish Registry Followed 132,585 People From Diagnosis Onward

Ternhamar’s team used Denmark’s national health registers, which track prescriptions, diagnoses and hospital visits for nearly the entire population, to identify everyone who developed type 2 diabetes between 2006 and 2019 without having previously taken a statin. That approach avoided a common weakness in studies of long-term drug use: relying on people to accurately recall when they started a medication years earlier.

Because the registry captures prescription fill dates directly, the researchers could sort the group by exactly how soon after diagnosis each person started statin therapy, rather than lumping all statin users into a single category regardless of timing. That distinction turned out to matter more than whether someone took a statin at all. The cohort was followed for up to a decade, giving the analysis enough time to observe dementia diagnoses that typically take years to accumulate in any population-level study.

Timing After Diagnosis, Not Just Statin Use, Drove the Difference

People who began statin treatment within a year of their diabetes diagnosis showed the lowest relative dementia risk in the study, at 15% below those who never started statins during the follow-up window. Ternhamar’s group found that risk reduction shrank the longer someone waited to start the drug after diagnosis, suggesting the protective association was tied to early intervention rather than to statins as a category regardless of when treatment began.

Ternhamar has described the pattern as consistent with statins doing more good the earlier they are introduced into a person’s post-diagnosis care, before vascular damage linked to diabetes has had years to accumulate. The registry data cannot pin down the exact biological point at which delay erodes the benefit, only that the association weakens as the gap between diagnosis and treatment widens.

Cholesterol Control Is Only Part of a Possible Brain Mechanism

Statins are prescribed to lower LDL cholesterol, and high cholesterol is itself a known risk factor for vascular problems that can contribute to dementia. But researchers studying statins and cognition have increasingly pointed to effects beyond cholesterol alone, including the drugs’ anti-inflammatory properties and their effect on blood vessel lining throughout the body, including small vessels in the brain.

Diabetes accelerates damage to exactly those small blood vessels, which is one reason vascular dementia risk rises after a diagnosis. A drug that both lowers cholesterol and calms vascular inflammation early, before that damage compounds, offers a plausible mechanism for why timing showed up as a stronger signal than statin use measured on its own. Alzheimer’s disease and vascular dementia are usually studied as separate conditions with different underlying causes, and the registry analysis did not report whether the 15% reduction was concentrated in one form of dementia over the other.

An Observational Study Cannot Prove Statins Caused the Lower Risk

The study, published in The Lancet Regional Health – Europe, is observational, meaning it tracked what people already did rather than randomly assigning some to start statins early and others to wait. That design cannot rule out the possibility that people who started statins sooner also had other health habits or better access to care that independently lowered their dementia risk.

The European Society of Cardiology’s summary of the research frames the 15% figure as an association rather than a proven cause, language Ternhamar has echoed in describing next steps for the work. A randomized trial testing early versus delayed statin initiation after a diabetes diagnosis, tracking dementia outcomes specifically, would be needed to confirm whether the timing itself is doing the work the registry data suggests.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview